# Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

> **NCT02015728** · NA · UNKNOWN · sponsor: **Seattle Children's Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Recurrent Childhood Brain Tumor

## Interventions

- **DEVICE:** Tumor biology testing
- **DRUG:** Temozolomide
- **DRUG:** Etoposide
- **DRUG:** Sorafenib
- **DRUG:** Everolimus
- **DRUG:** Erlotinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT02015728
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-12
- **Primary completion:** 2016-11
- **Final completion:** 2017-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2016-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015728, "Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02015728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*